BibTex format
@article{Cui:2026:10.1016/S2468-1253(25)00375-9,
author = {Cui, F and Faini, D and Razavi-Shearer, D and Razavi, H and Manzengo, Mingiedi C and Gonzalez, MA and Sabry, Alaama A and Mozalevskis, A and Chan, P and Izumi, K and Ghrabi, MA and Doherty, M and Olufunmilayo, L and Luhmann, N and de, Martel C and Dirac, M and Hallett, TB and Nayagam, S and Vickerman, P and Low-Beer, D},
doi = {10.1016/S2468-1253(25)00375-9},
journal = {Lancet Gastroenterol Hepatol},
pages = {509--520},
title = {The burden of chronic hepatitis B and C in 2022 and progress towards elimination: a global report.},
url = {http://dx.doi.org/10.1016/S2468-1253(25)00375-9},
volume = {11},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: WHO has worked closely with member states to set baseline targets, monitor progress and gaps, and develop a strategy to achieve the elimination of viral hepatitis as a public health threat by 2030. This analysis aimed to use the latest data to assess global progress, identify gaps, and provide strategic support to countries and regions to scale up prevention and treatment services to meet global, regional, and country-level targets. METHODS: Data on key indicators for 2022 were collated in 2023, including prevalence, incidence, mortality, and the cascade of care for chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infections. WHO country offices, regional offices, related departments, and partners were involved to verify and ensure the quality and completeness of the data. Data from 2022 were compared with historical data to monitor progress, and reported data were compared with expected data and targets to identify gaps in incidence and mortality. FINDINGS: As of June 30, 2023, WHO had received verified data reports from 187 of 194 countries and territories, including data contributions from collaborative partners. We estimated that, in 2022, globally, 254 million (3·27%) of 7758 million people were living with chronic HBV infection and 50 million (0·65%) people were living with HCV infection. Overall, five countries (China [83·7 million; 27·5%], India [35·3 million; 11·6%], Indonesia [18·9 million; 6·2%], Nigeria [15·7 million; 5·2%], and Pakistan [12·6 million; 4·2%]) accounted for 55% of the combined global burden of HBV and HCV. There were more than 2·2 million (95% CI 1·8-2·7) new chronic HBV and HCV infections and more than 1·3 million (95% CI 1·1-1·6) deaths due to HBV and HCV in 2022, with the majority of deaths due to HBV (1·1 million [95% CI 0·98-1·24]); as a result, the point est
AU - Cui,F
AU - Faini,D
AU - Razavi-Shearer,D
AU - Razavi,H
AU - Manzengo,Mingiedi C
AU - Gonzalez,MA
AU - Sabry,Alaama A
AU - Mozalevskis,A
AU - Chan,P
AU - Izumi,K
AU - Ghrabi,MA
AU - Doherty,M
AU - Olufunmilayo,L
AU - Luhmann,N
AU - de,Martel C
AU - Dirac,M
AU - Hallett,TB
AU - Nayagam,S
AU - Vickerman,P
AU - Low-Beer,D
DO - 10.1016/S2468-1253(25)00375-9
EP - 520
PY - 2026///
SP - 509
TI - The burden of chronic hepatitis B and C in 2022 and progress towards elimination: a global report.
T2 - Lancet Gastroenterol Hepatol
UR - http://dx.doi.org/10.1016/S2468-1253(25)00375-9
UR - https://www.ncbi.nlm.nih.gov/pubmed/41895313
VL - 11
ER -